Endogenous Regulator of G Protein Signaling 14 (RGS14) Suppresses Cocaine-induced Emotionally Motivated Behaviors in Female Mice

Overview

Journal bioRxiv

Date 2024 Sep 24

PMID 39314405

Authors

Sara N Bramlett

Stephanie L Foster

David Weinshenker

John R Hepler

Affiliations

Soon will be listed here.

Abstract

Addictive drugs hijack the neuronal mechanisms of learning and memory in motivation and emotion processing circuits to reinforce their own use. Regulator of G-protein Signaling 14 (RGS14) is a natural suppressor of post-synaptic plasticity underlying learning and memory in the hippocampus. The present study used immunofluorescence and RGS14 knockout mice to assess the role of RGS14 in behavioral plasticity and reward learning induced by chronic cocaine in emotional-motivational circuits. We report that RGS14 is strongly expressed in discrete regions of the ventral striatum and extended amygdala in wild-type mice, and is co-expressed with D1 and D2 dopamine receptors in neurons of the nucleus accumbens (NAc). Of note, we found that RGS14 is upregulated in the NAc in mice with chronic cocaine history following acute cocaine treatment. We found significantly increased cocaine-induced locomotor sensitization, as well as enhanced conditioned place preference and conditioned locomotor activity in RGS14-deficient mice compared to wild-type littermates. Together, these findings suggest that endogenous RGS14 suppresses cocaine-induced plasticity in emotional-motivational circuits, implicating RGS14 as a protective agent against the maladaptive neuroplastic changes that occur during addiction.

References

Hunt Jr A, Dasgupta R, Rajamanickam S, Jiang Z, Beierlein M, Chan C . Paraventricular hypothalamic and amygdalar CRF neurons synapse in the external globus pallidus. Brain Struct Funct. 2018; 223(6):2685-2698. PMC: 5997534. DOI: 10.1007/s00429-018-1652-y. View

Squires K, Gerber K, Tillman M, Lustberg D, Montanez-Miranda C, Zhao M . Human genetic variants disrupt RGS14 nuclear shuttling and regulation of LTP in hippocampal neurons. J Biol Chem. 2021; 296:100024. PMC: 7949046. DOI: 10.1074/jbc.RA120.016009. View

Cahill E, Salery M, Vanhoutte P, Caboche J . Convergence of dopamine and glutamate signaling onto striatal ERK activation in response to drugs of abuse. Front Pharmacol. 2014; 4:172. PMC: 3884214. DOI: 10.3389/fphar.2013.00172. View

Pego J, Morgado P, Pinto L, Cerqueira J, Almeida O, Sousa N . Dissociation of the morphological correlates of stress-induced anxiety and fear. Eur J Neurosci. 2008; 27(6):1503-16. DOI: 10.1111/j.1460-9568.2008.06112.x. View

Koob G, Volkow N . Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry. 2016; 3(8):760-773. PMC: 6135092. DOI: 10.1016/S2215-0366(16)00104-8. View

Lee S, Simons S, Heldt S, Zhao M, Schroeder J, Vellano C . RGS14 is a natural suppressor of both synaptic plasticity in CA2 neurons and hippocampal-based learning and memory. Proc Natl Acad Sci U S A. 2010; 107(39):16994-8. PMC: 2947872. DOI: 10.1073/pnas.1005362107. View

Becker W, Fiellin D, Desai R . Non-medical use, abuse and dependence on sedatives and tranquilizers among U.S. adults: psychiatric and socio-demographic correlates. Drug Alcohol Depend. 2007; 90(2-3):280-7. PMC: 3745028. DOI: 10.1016/j.drugalcdep.2007.04.009. View

Berke J, Hyman S . Addiction, dopamine, and the molecular mechanisms of memory. Neuron. 2000; 25(3):515-32. DOI: 10.1016/s0896-6273(00)81056-9. View

Tokutake T, Asano T, Miyanishi H, Nakaya S, Izuo N, Nitta A . Cannabinoid Type 1 Receptors in the Basolateral Amygdala Regulate ACPA-Induced Place Preference and Anxiolytic-Like Behaviors. Neurochem Res. 2022; 47(9):2899-2908. DOI: 10.1007/s11064-022-03708-8. View

10.

Vellano C, Brown N, Blumer J, Hepler J . Assembly and function of the regulator of G protein signaling 14 (RGS14)·H-Ras signaling complex in live cells are regulated by Gαi1 and Gαi-linked G protein-coupled receptors. J Biol Chem. 2012; 288(5):3620-31. PMC: 3561580. DOI: 10.1074/jbc.M112.440057. View

11.

Kupchik Y, Kalivas P . The Direct and Indirect Pathways of the Nucleus Accumbens are not What You Think. Neuropsychopharmacology. 2016; 42(1):369-370. PMC: 5143491. DOI: 10.1038/npp.2016.160. View

12.

Glangetas C, Girard D, Groc L, Marsicano G, Chaouloff F, Georges F . Stress switches cannabinoid type-1 (CB1) receptor-dependent plasticity from LTD to LTP in the bed nucleus of the stria terminalis. J Neurosci. 2013; 33(50):19657-63. PMC: 6618762. DOI: 10.1523/JNEUROSCI.3175-13.2013. View

13.

Wu L, Howard M . Psychiatric disorders in inhalant users: results from The National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend. 2006; 88(2-3):146-55. PMC: 1934509. DOI: 10.1016/j.drugalcdep.2006.10.012. View

14.

Li Y, Acerbo M, Robinson T . The induction of behavioural sensitization is associated with cocaine-induced structural plasticity in the core (but not shell) of the nucleus accumbens. Eur J Neurosci. 2004; 20(6):1647-54. DOI: 10.1111/j.1460-9568.2004.03612.x. View

15.

Lee R, Geracioti Jr T, Kasckow J, Coccaro E . Childhood trauma and personality disorder: positive correlation with adult CSF corticotropin-releasing factor concentrations. Am J Psychiatry. 2005; 162(5):995-7. DOI: 10.1176/appi.ajp.162.5.995. View

16.

Badiani A, Robinson T . Drug-induced neurobehavioral plasticity: the role of environmental context. Behav Pharmacol. 2004; 15(5-6):327-39. DOI: 10.1097/00008877-200409000-00004. View

17.

Thibault D, Loustalot F, Fortin G, Bourque M, Trudeau L . Evaluation of D1 and D2 dopamine receptor segregation in the developing striatum using BAC transgenic mice. PLoS One. 2013; 8(7):e67219. PMC: 3699584. DOI: 10.1371/journal.pone.0067219. View

18.

Mantsch J . Corticotropin releasing factor and drug seeking in substance use disorders: Preclinical evidence and translational limitations. Addict Neurosci. 2022; 4. PMC: 9757758. DOI: 10.1016/j.addicn.2022.100038. View

19.

Beyermann M, Heinrich N, Fechner K, Furkert J, Zhang W, Kraetke O . Achieving signalling selectivity of ligands for the corticotropin-releasing factor type 1 receptor by modifying the agonist's signalling domain. Br J Pharmacol. 2007; 151(6):851-9. PMC: 2014118. DOI: 10.1038/sj.bjp.0707293. View

20.

Kravitz A, Freeze B, Parker P, Kay K, Thwin M, Deisseroth K . Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature. 2010; 466(7306):622-6. PMC: 3552484. DOI: 10.1038/nature09159. View